Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis

Journal of Neurology

Volumn 259, Issue 7, 2012, Pages 1312-1316

  Romi, Fredrik ^a   Suzuki, Shigeaki ^b   Suzuki, Norihiro ^b   Petzold, Axel ^c,d   Plant, Gordon T ^e,f,g   Gilhus, Nils Erik ^a,h  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b KEIO UNIVERSITY   (Japan)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^f MOORFIELDS EYE HOSPITAL   (United Kingdom)

^g ST THOMAS HOSPITAL   (United Kingdom)

^h UNIVERSITY OF BERGEN   (Norway)

Author keywords

Anti Kv1.4 antibodies; Myasthenia gravis

Indexed keywords

ANTIBODY; IMMUNOSUPPRESSIVE AGENT; POTASSIUM CHANNEL KV1.4; POTASSIUM CHANNEL KV1.4 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CAUCASIAN; CLINICAL FEATURE; ELECTROCARDIOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; JAPANESE; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; MYOCARDITIS; PRIORITY JOURNAL; QT PROLONGATION; THYMECTOMY; THYMOMA;

ADULT; AGE OF ONSET; AGED; AUTOANTIBODIES; FEMALE; HUMANS; JAPAN; KV1.4 POTASSIUM CHANNEL; MAGNETIC RESONANCE IMAGING; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; MYASTHENIA GRAVIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; SEX FACTORS;

EID: 84864285924     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-011-6344-y     Document Type: Article

References (22)

1. Lindstrøm JM, Seybold ME, Lennon VA, Whittingham S, Duane DD (1998) Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. 1975 classical article. Neurology 51:933-939
2. Evoli A, Batocchi AP, Minisci C, Di Schino C, Tonali P (2001) Therapeutic options in ocular myasthenia gravis. Neuromuscul Disord 11:208-216 (Pubitemid 32201147)
3. Luchanok U, Kaminski HJ (2008) Ocular myasthenia: diagnostic and treatment recommendations and the evidence base. Curr Opin Neurol 21:8-15
4. WilcoxN(1993)Myasthenia gravis. Curr Opin Immunol 5:910-917
5. Li Z, Forester N, Vincent A (1996) Modulation of acetylcholine receptor function in TE671 (rhabdomyocyosarcoma) cells by non-AChR ligands: possible relevance to seronegative myasthenia gravis. J Neuroimmunol 64:179-183 (Pubitemid 26094634)
6. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7:365-368 (Pubitemid 32224355)
7. McConville J, Farrugia ME, Beeson D, Kishore U, Metcalfe R, Newsom-Davis J, Vincent A (2004) Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 55:580-584 (Pubitemid 38391977)
8. Fuhrer C, Sugiyama JE, Taylor RG, Hall ZW (1997) Association of muscle-specific kinase MuSK with the acetylcholine receptor in mammalian muscle. EMBO J 16:4951-4960 (Pubitemid 27348404)
9. Borges LS, Ferns M (2001) Agrin-induced phosphorylation of the acetylcholine receptor regulates cytoskeletal anchoring and clustering. J Cell Biol 153:1-12
10. Romi F, Gilhus NE, Luckman S (2008) Serum matrix metalloproteinase-3 (MMP-3) levels are elevated in myasthenia gravis. J Neuroimmunol 195:96-99
11. Helgeland G, Petzold A, Luckman SP, Gilhus NE, Plant GT, Romi F (2011) Matrix metalloproteinases in myasthenia gravis. Eur Neurol 65:53-58
12. Romi F, Skeie GO, Gilhus NE, Aarli JA (2005) Striational antibodies in myasthenia gravis: reactivity and possible clinical significance. Arch Neurol 62:442-446 (Pubitemid 40349480)
13. Helgeland G, Petzold A, Hoff JM, Gilhus NE, Plant GT, Romi FR (2010) Anti-heat shock protein 70 antibody levels are increased in myasthenia gravis and Guillain-Barré syndrome. J Neuroimmunol 225:180-183
14. Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani L, Peles E, Buckley C, Lang B, Vincent A (2010) Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 133(9):2734-2748
15. Lai M, Huijbers MG, Lancaster E, Graus F, Bataller L, Balice-Gordon R, Cowell JK, Dalmau J (2010) Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 9(8):776-785
16. Tan KM, Lennon VA, Klein CJ, Boeve BF, Pittock SJ (2008) Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology 70(20):1883-1890 (Pubitemid 351684641)
17. Suzuki S, Utsugisawa K, Nagane Y, Suzuki N (2011) Three types of striational antibodies in myasthenia gravis. Autoimmune Dis 2011:740583
18. Yellen G (2002) The voltage-gated potassium channels and their relatives. Nature 419:35-42 (Pubitemid 34987863)
19. Suzuki S, Satoh T, Yasuoka H, Hamaguchi Y, Tanaka K, Kawakami Y, Suzuki N, Kuwana M (2005) Novel autoantibodies to a voltage-gated potassium channel Kv1.4 in a severe form of myasthenia gravis. J Neuroimmunol 170(1-2):141-149 (Pubitemid 41740915)
20. Meriggioli MN, Sanders DB (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8(5):475-490
21. Suzuki S, Utsugisawa K, Nagane Y, Satoh T, Kuwana M, Suzuki N (2011) Clinical and immunological differences between early and late-onset myasthenia gravis in Japan. J Neuroimmunol 230(1-2):148-152
22. Wickenden AD, Jegla TJ, Kaprielian R, Backx PH (1999) Regional contributions of KV1.4, KV4.2, and KV4.3 to transient outward K+ current in rat ventricle. Am J Physiol 276:H1599-H1607 (Pubitemid 29246547)